2025,Sawada S, Asao K, Kobayashi R, Bosco J, Maeda H. Characterization of Japanese Risk Management Plans after 10 Years of Implementation: 2013-2023. Ther Innov Regul Sci. 2025 Jun 3. doi: 10.1007/s43441-025-00818-7. 2025年6月9日 論文
2025,Hirano S, Hanada K, Maeda H. Potential surrogate endpoint for B-cell hematologic malignancy: A systematic review and meta-analysis. Sci Rep. 2025 Jun 2;15(1):19300. doi: 10.1038/s41598-025-05053-6. 2025年6月9日 論文
2025,Hakariya H, Ozaki A, Hashimoto T, Moriarty F, Maeda H, Tanimoto T. Added Therapeutic Benefits of Top-Selling Drugs in Japan: A Cross-Sectional Study Using Health Technology Assessment. Clin Transl Sci. 2025 Jun;18(6):e70243. doi: 10.1111/cts.70243. 2025年6月9日 論文
2025, Kitagaki H, Takeda K, Murai K, Maeda H. Dose Optimization in Oncology Drug Development: Risk Factors for Postmarketing Requirements and Commitments. Clin Pharmacol Ther. 2025 May 20. doi: 10.1002/cpt.3722. 2025年5月20日 論文
2025,Kobayashi K, Inaba Y, Hashimoto M, Maeda H. Cross-sectional Study and Comparison between Japan and the United States on Special Regulatory Pathways for Expedited Drug Development and Approval. Therapeutic Innovation & Regulatory Science. 2025. https://doi.org/10.1007/s43441-025-00771-5. 2025年5月20日 論文
2025, Nakatani S, Hayashi T, Yamamoto K, Maeda H. Impact of loss of HER2 positivity following neoadjuvant therapy in HER2-positive breast cancer patients on long-term prognosis: A systematic review and meta-analysis.Cancer Treatment Reviews. 2025. 135: 102923. 2025年3月21日 論文
2025, Maeda H, Soh H, Hashimoto M, Han E, Ohno E. Gender differences in pharmacy professors in Japan and Korea. The Lancet Regional Health Western Pacific. 2025 Jan. doi:10.1016/j.lanwpc.2025.101469. 2025年1月29日 論文
2024, Kameyama N, Hosaka A, Maeda H. Has risk management plan system influenced the speed of package insert revisions in Japan? Front Med. 2024 Oct. DOI: 10.3389/fmed.2024.1465313. 2024年10月29日 論文
2024, Edo K, Kawano M, Maeda H. Comparison of regulatory approval system for medicines in emergency among Japan, the United States, the United Kingdom, Europe, and China. PLoS One. 2024 Sep; 19(9): e0309992. https://doi.org/ 10.1371/journal.pone.0309992. 2024年9月17日 論文
2024, Mochizuki M and Maeda H. Trends in the market for drug delivery devices categorized as combination drugs and medical devices and regulatory challenges for autoinjectors in Japan. Frontiers in Medical Technology. 2024 Aug; doi: https://doi.org/10.3389/fmedt.2024.1461460 2024年8月6日 論文
2024, Hayashi H, Nogita T, Maeda H. A Qualitative Interview Study on Expanded Access Clinical Trials for Compassionate Use in Japan. Patient Prefer Adherence. 2024 Jul 11;18:1471-1479. 2024年7月17日 論文
2024, Kameyama N, Hosaka A, and Maeda H. Current situation and issues regarding termination of risk management plans in Japan. Front Med. 2024 May;doi: https://doi.org/10.3389/fmed.2024.1387652 2024年5月30日 論文
2024, Hiramatsu K, Maeda H. Adult and pediatric relapsing multiple sclerosis phase II and phase III trial design and their primary end points: A systematic review. Clin Transl Sci. 2024 May;17(5):e13794. doi: 10.1111/cts.13794. 2024年5月7日 論文
2024, 前田 英紀．タイの医療保障制度について Health Security Systems in Thailand. Monthly IHEP：337(2)31-36. 2024年2月2日 論文
2023, Maeda H, Hara A, Ofuchi M, Shingai R, Misumi T, Murai Y. Trends in oncology drug lags in Japan from 2001 to 2020: A cross-sectional study. Clin Transl Sci. 2023 Oct 10. doi: 10.1111/cts.13660. 2023年10月18日 論文
